This study aims to investigate the possible efficacy and safety of L-Arginine in children having Sickle Cell Disease with increased Tricuspid Regurgitant Jet Velocity
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
50
L-Arginine 1000 mg free form, rapid release capsules
Tanta university
Tanta, Other (Non U.s.), Egypt
change in tricuspid regurgitant jet velocity (TRJV) detected by Color Doppler Echocardiography
patients will undergo Color Doppler Echocardiography to assess tricuspid regurgitant jet velocity (TRJV) at baseline and after 3 months
Time frame: 3 months
change in serum level of N-terminal pro b-type natriuretic peptide (NT-pro-BNP)
Blood samples will be collected at baseline and after 3 months
Time frame: 3 months
change in serum level of L-Arginine
Blood samples will be collected at baseline and after 3 months
Time frame: 3 months
change in serum level of Asymmetric Dimethyl Arginine (ADMA)
Blood samples will be collected at baseline and after 3 months
Time frame: 3 months
change in serum level of Nitric Oxide
Blood samples will be collected at baseline and after 3 months
Time frame: 3 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.